双化合物在母乳和婴儿配方奶粉中的全球存在:系统性审查
Hamid Ahmadpourmir1, Masomeh Moradzehi2, Mahin Velayati3
1Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Food research international (Ottawa, Ont.)
|May 13, 2025
概括
双化合物 (BPs),如双A (BPA),在婴儿饮食中发现. 乙是一种常见的内分泌干扰物,由于潜在的健康风险,通过母乳和配方奶粉监测婴儿暴露至关重要.
科学领域:
- 环境化学环境化学
- 毒理学 毒理学 毒理学
- 公共卫生 公共卫生
背景情况:
- 双化合物 (BPs),包括双A (BPA),是广泛使用的工业化学品,具有记录的有毒作用,如内分泌干扰.
- 婴儿在关键发育阶段对化学物质暴露特别容易受到伤害.
- 通过母乳和婴儿配方奶粉监测BP暴露对于婴儿健康至关重要.
研究的目的:
- 系统地审查和分析母乳和婴儿配方奶粉中双化合物 (BPs) 的存在情况.
- 在这些矩阵中识别最频繁检测到的BP及其度水平.
- 评估目前对BPA类型的数据可用性,并突出研究缺口.
主要方法:
- 在PubMed和Scopus数据库中进行系统的文献搜索.
- 包括44项分析母乳和/或婴儿配方奶粉样本BP含量的研究.
- 检测方法的分析,主要是液体染色学-并联质谱学 (HPLC-MS/MS) 和气体染色学-质谱学 (GC-MS).
主要成果:
- 双A (BPA) 是母乳和婴儿配方奶粉中最频繁检测到的BP.
- 在母乳中 (台湾) 的BPA度高达112.44ng/g,在配方奶中 (加拿大) 达到262ng/g.
- 关于BPA类似物如双S (BPS) 和双F (BPF) 的数据很少.
结论:
- 双甲在婴儿饮食中通过母乳和配方奶粉普遍存在.
- 目前的分析方法对于检测BP是有效的,HPLC-MS/MS和GC-MS是常见的.
- 在这些重要的婴儿营养来源中,对BPA类型的发生和水平进行更多研究是非常必要的.
相关概念视频
01:07Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410